Alder BioPharmaceuticals

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.
Company Growth (employees)
Type
Public
HQ
Bothell, US
Founded
2004
Size (employees)
176 (est)+56%
Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, US

Key People at Alder BioPharmaceuticals

Randall Schatzman

Randall Schatzman

President & CEO
John Latham

John Latham

Chief Scientific Officer
Larry Benedict

Larry Benedict

Vice President, Finance
Mark Litton

Mark Litton

Chief Business Officer and Treasurer

Alder BioPharmaceuticals Office Locations

Alder BioPharmaceuticals has an office in Bothell
Bothell, US (HQ)
11804 North Creek Parkway

Alder BioPharmaceuticals Data and Metrics

Alder BioPharmaceuticals Financial Metrics

$, USD

Net income (FY, 2016)

(156.3 m)

EBIT (FY, 2016)

(157.9 m)

Market capitalization (23-Jun-2017)

993.1 m

Closing share price (23-Jun-2017)

19.4

Cash (31-Dec-2016)

116.2 m
Alder BioPharmaceuticals's current market capitalization is $993.1 m.
$, USDFY, 2014FY, 2015FY, 2016

Cost of goods sold

113 k

R&D expense

33.4 m69.6 m132.8 m

General and administrative expense

12.5 m16.7 m26.1 m

Operating expense total

45.9 m86.3 m159 m

EBIT

8.8 m(86.3 m)(157.9 m)

Interest expense

(88 k)

Interest income

44 k702 k2 m

Net Income

8.9 m(85.5 m)(156.3 m)
$, USDFY, 2014FY, 2015FY, 2016

Cash

46.8 m206.5 m116.2 m

Accounts Receivable

113 k113 k

Inventories

28.2 m936 k

Current Assets

60.7 m322.2 m393.2 m

PP&E

1.2 m2 m7.1 m

Total Assets

64.4 m400 m409.2 m

Accounts Payable

1.9 m4.7 m10.4 m

Current Liabilities

5 m12.4 m25.9 m

Additional Paid-in Capital

196.1 m610.4 m761.5 m

Retained Earnings

(136.9 m)(222.4 m)(378.6 m)

Total Equity

387.5 m382.8 m

Financial Leverage

1 x1.1 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

8.9 m(85.5 m)(156.3 m)

Depreciation and Amortization

701 k751 k1.7 m

Accounts Receivable

203 k113 k113 k

Inventories

95 k(936 k)

Accounts Payable

(312 k)2.8 m5.5 m

Cash From Operating Activities

(47.7 m)(81.2 m)(159.7 m)

Purchases of PP&E

(649 k)(1.2 m)(6.6 m)

Cash From Investing Activities

(9.7 m)(167.3 m)(67.7 m)

Cash From Financing Activities

81 m408.2 m137.1 m
Y, 2016

Financial Leverage

1.1 x

Alder BioPharmaceuticals Market Value History

Alder BioPharmaceuticals Online and Social Media Presence

Alder BioPharmaceuticals Company Life and Culture

You may also be interested in